FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310863084> ?p ?o ?g. }

• W4310863084 endingPage "e2244652" @default.
• W4310863084 startingPage "e2244652" @default.
• W4310863084 abstract "Importance Patients with COVID-19 have a high prevalence of diabetes, and diabetes and blood glucose control are determinants of intensive care unit admission and mortality. Objective To evaluate the association between COVID-19–related adverse outcomes and 8 antihyperglycemic drugs in patients with diabetes who were subsequently diagnosed and hospitalized with COVID-19. Data Sources Data were retrieved and collected in PubMed, Embase, Cochrane Central Register, Web of Science, and ClinicalTrials.gov from database inception to September 5, 2022. Study Selection For this systematic review and network meta-analysis, randomized clinical trials and observational studies conducted among patients with diabetes while receiving glucose-lowering therapies for at least 14 days before the confirmation of COVID-19 infection were included after blinded review by 2 independent reviewers and consultations of disagreement by a third independent reviewer. Of 1802 studies initially identified, 31 observational studies met the criteria for further analysis. Data Extraction and Synthesis This study follows the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline. Bayesian network meta-analyses were performed with random effects. Main Outcomes and Measures A composite adverse outcome, including the need for intensive care unit admission, invasive and noninvasive mechanical ventilation, or in-hospital death. Results Thirty-one distinct observational studies (3 689 010 patients with diabetes hospitalized for COVID-19) were included. The sodium-glucose cotransporter-2 inhibitors (SGLT-2is) were associated with relatively lower risks of adverse outcomes compared with insulin (log of odds ratio [logOR], 0.91; 95% credible interval [CrI], 0.57-1.26), dipeptidyl peptidase-4 inhibitors (logOR, 0.61; 95% CrI, 0.28-0.93), secretagogues (logOR, 0.37; 95% CrI, 0.02-0.72), and glucosidase inhibitors (logOR, 0.50; 95% CrI, 0.00-1.01). Based on the surface under the cumulative ranking curves value, SGLT-2is were associated with the lowest probability for adverse outcomes (6%), followed by glucagon-like peptide-1 receptor agonists (25%) and metformin (28%). A sensitivity analysis revealed that the study was reliable. Conclusions and Relevance These findings suggest that the use of an SGLT-2i before COVID-19 infection is associated with lower COVID-19–related adverse outcomes. In addition to SGLT-2is, glucagon-like peptide-1 receptor agonists and metformin were also associated with relatively low risk of adverse outcomes." @default.
• W4310863084 created "2022-12-19" @default.
• W4310863084 creator A5003383875 @default.
• W4310863084 creator A5045067652 @default.
• W4310863084 creator A5049687714 @default.
• W4310863084 creator A5053114271 @default.
• W4310863084 creator A5088141818 @default.
• W4310863084 date "2022-12-06" @default.
• W4310863084 modified "2023-10-09" @default.
• W4310863084 title "Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19" @default.
• W4310863084 cites W2010699829 @default.
• W4310863084 cites W2027388546 @default.
• W4310863084 cites W2068815946 @default.
• W4310863084 cites W2091808438 @default.
• W4310863084 cites W2144625636 @default.
• W4310863084 cites W2413462519 @default.
• W4310863084 cites W2473725818 @default.
• W4310863084 cites W2515456868 @default.
• W4310863084 cites W2900413769 @default.
• W4310863084 cites W2914947684 @default.
• W4310863084 cites W2939443580 @default.
• W4310863084 cites W2968669882 @default.
• W4310863084 cites W3000701538 @default.
• W4310863084 cites W3001829806 @default.
• W4310863084 cites W3015524861 @default.
• W4310863084 cites W3015622053 @default.
• W4310863084 cites W3018002427 @default.
• W4310863084 cites W3020168167 @default.
• W4310863084 cites W3021684016 @default.
• W4310863084 cites W3024432354 @default.
• W4310863084 cites W3029761253 @default.
• W4310863084 cites W3031959493 @default.
• W4310863084 cites W3032236843 @default.
• W4310863084 cites W3034077604 @default.
• W4310863084 cites W3034800679 @default.
• W4310863084 cites W3035915732 @default.
• W4310863084 cites W3039703269 @default.
• W4310863084 cites W3040818588 @default.
• W4310863084 cites W3047144258 @default.
• W4310863084 cites W3081830235 @default.
• W4310863084 cites W3083980445 @default.
• W4310863084 cites W3091602118 @default.
• W4310863084 cites W3092037124 @default.
• W4310863084 cites W3092471842 @default.
• W4310863084 cites W3097679797 @default.
• W4310863084 cites W3097749910 @default.
• W4310863084 cites W3099955745 @default.
• W4310863084 cites W3103267577 @default.
• W4310863084 cites W3109318760 @default.
• W4310863084 cites W3110070901 @default.
• W4310863084 cites W3110668269 @default.
• W4310863084 cites W3111430313 @default.
• W4310863084 cites W3119033482 @default.
• W4310863084 cites W3121988933 @default.
• W4310863084 cites W3133451197 @default.
• W4310863084 cites W3137221280 @default.
• W4310863084 cites W3149407925 @default.
• W4310863084 cites W3149541685 @default.
• W4310863084 cites W3159102338 @default.
• W4310863084 cites W3159133464 @default.
• W4310863084 cites W3170966862 @default.
• W4310863084 cites W3188701750 @default.
• W4310863084 cites W3196797224 @default.
• W4310863084 cites W3198994215 @default.
• W4310863084 cites W3201948739 @default.
• W4310863084 cites W3206648388 @default.
• W4310863084 cites W3209878863 @default.
• W4310863084 cites W3212514328 @default.
• W4310863084 cites W4200433439 @default.
• W4310863084 cites W4206257923 @default.
• W4310863084 cites W4206262981 @default.
• W4310863084 cites W4210624236 @default.
• W4310863084 cites W4224949174 @default.
• W4310863084 cites W4280494017 @default.
• W4310863084 cites W4280507539 @default.
• W4310863084 cites W4281861721 @default.
• W4310863084 cites W4282941255 @default.
• W4310863084 cites W4284889033 @default.
• W4310863084 doi "https://doi.org/10.1001/jamanetworkopen.2022.44652" @default.
• W4310863084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36472874" @default.
• W4310863084 hasPublicationYear "2022" @default.
• W4310863084 type Work @default.
• W4310863084 citedByCount "6" @default.
• W4310863084 countsByYear W43108630842023 @default.
• W4310863084 crossrefType "journal-article" @default.
• W4310863084 hasAuthorship W4310863084A5003383875 @default.
• W4310863084 hasAuthorship W4310863084A5045067652 @default.
• W4310863084 hasAuthorship W4310863084A5049687714 @default.
• W4310863084 hasAuthorship W4310863084A5053114271 @default.
• W4310863084 hasAuthorship W4310863084A5088141818 @default.
• W4310863084 hasBestOaLocation W43108630841 @default.
• W4310863084 hasConcept C126322002 @default.
• W4310863084 hasConcept C134018914 @default.
• W4310863084 hasConcept C156957248 @default.
• W4310863084 hasConcept C168563851 @default.
• W4310863084 hasConcept C17744445 @default.
• W4310863084 hasConcept C177713679 @default.
• W4310863084 hasConcept C194828623 @default.

• next